Exposure of NK cells to intravenous immunoglobulin induces IFNγ release and degranulation but inhibits their cytotoxic activity

Clinical Immunology

Volumn 133, Issue 3, 2009, Pages 393-401

  Jacobi, Christian ^a   Claus, Maren ^a   Wildemann, Brigitte ^a   Wingert, Sabine ^a   Korporal, Mirjam ^a   Römisch, Jürgen ^b   Meuer, Stefan ^a   Watzl, Carsten ^a   Giese, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Octapharma PPGmbH   (Austria)

Author keywords

CD107a; Cytolytic activity; Fc gammaRIII; IFN ; IVIg; Natural Killer cells

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; GRANZYME B; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ANTIGEN EXPRESSION; ARTICLE; ASSAY; BLOOD; BLOOD EXAMINATION; CELL COUNT; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DEGRANULATION; DRUG EFFECT; DRUG INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANTIGENS, CD; AUTOIMMUNE DISEASES; CELL DEGRANULATION; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GRANZYMES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MULTIPLE SCLEROSIS; PERFORIN; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 70350591843     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.09.006     Document Type: Article

References (30)

1. Negi V.S., Elluru S., Siberil S., Graff-Dubois S., Mouthon L., Kazatchkine M.D., Lacroix-Desmazes S., Bayry J., and Kaveri S.V. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 27 (2007) 233-245
2. Prins C., Gelfand E.W., and French L.E. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm. Venereol. 87 (2007) 206-218
3. Boros P., Gondolesi G., and Bromberg J.S. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transpl. 11 (2005) 1469-1480
4. Ephrem A., Misra N., Hassan G., Dasgupta S., Delignat S., Van Huyen J.P., Chamat S., Prost F., Lacroix-Desmazes S., Kavery S.V., and Kazatchkine M.D. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin. Exp. Med. 5 (2005) 135-140
5. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345 (2001) 747-755
6. Siberil S., Elluru S., Graff-Dubois S., Negi V.S., Delignat S., Mouthon L., Lacroix-Desmazes S., Kazatchkine M.D., Bayary J., and Kaveri S.V. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann. N.Y. Acad. Sci. 1110 (2007) 497-506
7. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., and Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320 (2008) 373-376
8. Nimmerjahn F. Activating and inhibitory FcgammaRs in autoimmune disorders. Springer Semin. Immunopathol. 28 (2006) 305-319
9. Nimmerjahn F., and Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26 (2008) 513-533
10. Engelhard D., Waner J.L., Kapoor N., and Good R.A. Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia. J. Pediatr. 108 (1986) 77-81
11. Kwak J.Y., Kwak F.M., Ainbinder S.W., Ruiz A.M., and Beer A.E. Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Am. J. Reprod. Immunol. 35 (1996) 363-369
12. Perricone R., Di Muzio G., Perricone C., Giacomelli R., De Nardo D., Fontana L., and De Carolis C. High levels of peripheral blood NK cells in women suffering from recurrent spontaneous abortion are reverted from high-dose intravenous immunoglobulins. Am. J. Reprod. Immunol. 55 (2006) 232-239
13. Roussev R.G., Ng S.C., and Coulam C.B. Natural killer cell functional activity suppression by intravenous immunoglobulin, intralipid and soluble human leukocyte antigen-G. Am. J. Reprod. Immunol. 57 (2007) 262-269
14. Tha-In T., Metselaar H.J., Tilanus H.W., Groothuismink Z.M., Kuipers E.J., de Man R.A., and Kwekkeboom J. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood 110 (2007) 3253-3262
15. Morikawa M., Yamada H., Kato E.H., Shimada S., Kishi T., Yamada T., Kobashi G., and Fujimoto S. Massive intravenous immunoglobulin treatment in women with four or more recurrent spontaneous abortions of unexplained etiology: down-regulation of NK cell activity and subsets. Am. J. Reprod. Immunol. 46 (2001) 399-404
16. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9 (2008) 495-502
17. Vivier E., Tomasello E., Baratin M., Walzer T., and Ugolini S. Functions of natural killer cells. Nat. Immunol. 9 (2008) 503-510
18. Cooper M.A., Fehniger T.A., and Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol. 22 (2001) 633-640
19. Claus M., Greil J., and Watzl C. Comprehensive analysis of NK cell function in whole blood samples. J. Immunol. Methods 341 (2009) 154-164
20. Bryant J., Day R., Whiteside T.L., and Herberman R.B. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J. Immunol. Methods 146 (1992) 91-103
21. Alter G., Malenfant J.M., and Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294 (2004) 15-22
22. Bhat R., and Watzl C. Serial killing of tumor cells by human natural killer cells-enhancement by therapeutic antibodies. PLoS ONE 2 (2007) e326
23. Bryceson Y.T., March M.E., Barber D.F., Ljunggren H.G., and Long E.O. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J. Exp. Med. 202 (2005) 1001-1012
24. Bryceson Y.T., March M.E., Ljunggren H.G., and Long E.O. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol. Rev. 214 (2006) 73-91
25. Hoetzenecker K., Hacker S., Hoetzenecker W., Sadeghi K., Sachet M., Pollreisz A., Mangold A., Wliszczak T., Bielek E., Muehlbacher F., Klepetko W., and Ankersmit H.J. Cytomegalovirus hyperimmunoglobulin: mechanisms in allo-immune response in vitro. Eur. J. Clin. Invest. 37 (2007) 978-986
26. Djoumerska I., Tchorbanov A., Pashov A., and Vassilev T. The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used. Scand. J. Immunol. 61 (2005) 357-363
27. Ling Z.D., Yeoh E., Webb B.T., Farrell K., Doucette J., and Matheson D.S. Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo. J. Clin. Immunol. 13 (1993) 302-309
28. Lunemann J.D., and Munz C. Do natural killer cells accelerate or prevent autoimmunity in multiple sclerosis?. Brain 131 (2008) 1681-1683
29. Morandi B., Bramanti P., Bonaccorsi I., Montalto E., Oliveri D., Pezzino G., Navarra M., and Ferlazzo G. Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol. Res. 57 (2008) 1-5
30. Qin H.Y., Mukherjee R., Lee-Chan E., Ewen C., Bleackley R.C., and Singh B. A novel mechanism of regulatory T cell-mediated down-regulation of autoimmunity. Int. Immunol. 18 (2006) 1001-1015